High Peak Estradiol Predicts Higher Miscarriage and Lower Live Birth Rates in High Responders Triggered with a GnRH Agonist in IVF/ICSI Cycles
|
|
- Melanie Booth
- 5 years ago
- Views:
Transcription
1 The Journal of Reproductive Medicine High Peak Estradiol Predicts Higher Miscarriage and Lower Live Birth Rates in High Responders Triggered with a GnRH Agonist in IVF/ICSI Cycles Ryan G. Steward, M.D., Cindy E. Zhang, M.D., Anish A. Shah, M.D., Jason S. Yeh, M.D., Chen Chen, M.S., Yi-Ju Li, Ph.D., Thomas M. Price, M.D., and Suheil J. Muasher, M.D. ORIGINAL ARTICLES OBJECTIVE: To investigate parameters predictive of pregnancy outcomes in high responders undergoing fresh, autologous, GnRH antagonist IVF/ICSI cycles using a GnRH agonist trigger. STUDY DESIGN: Retrospective cohort study of all patients deemed high-risk for ovarian hyperstimulation syndrome who underwent fresh, autologous IVF/ICSI using a GnRH agonist trigger at an academic fertility center from RESULTS: A total of 71 first cycles were analyzed. Rates of clinical pregnancy, live birth (LB), and total (clinical plus biochemical) miscarriage (MC) were 52%, 38%, and 25%, respectively. Mean peak estradiol (E2) and the number of oocytes retrieved were 3,701 pg/ml and 15.2, respectively. Peak E2 was significantly higher in those cycles resulting in clinical MC (p=0.003). After adjusting for age, basal follicle stimulating hormone, and the number of oocytes retrieved, elevated peak E2 remained Clinicians should recognize this patient population as inherently in danger of this scenario and minimize the occurrence of peak E2 levels >5,000 pg/ml. associated with increased clinical MC (p=0.029) and trended towards a relationship with higher total MC (p=0.062). When peak E2 was treated as a binary variable based on the threshold value of >5,000 pg/ml, peak E2 above this value was associated with a higher rate of clinical MC (OR=16.14 with 95% CI , p=0.033) and total MC (OR=6.81 with 95% CI , p=0.037), as well as a lower LB rate (OR= with 95% CI , p=0.041). CONCLUSION: Clinicians should recognize most IVF/ICSI patients triggered with a GnRH agonist as inherently in danger of excessively high serum E2 and avoid peak levels >5,000 pg/ml in order to avoid higher MC and lower LB rates. (J Reprod Med 2015;60: ) Keywords: agonists, assisted reproductive techniques, assisted reproductive technology, con- From the Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Duke University Medical Center; the Department of Biostatistics and Bioinformatics, Duke University Medical Center; and Duke Institute of Molecular Physiology, Duke University Medical Center, Durham, North Carolina. Presented as an oral presentation at the 69th American Society for Reproductive Medicine/International Federation of Fertility Societies Annual Meeting, Boston, Massachusetts, October 12 17, Address correspondence to: Ryan G. Steward, M.D., 5704 Fayetteville Road, Durham, NC (rgstew777@gmail.com). Financial Disclosure: The authors have no connection to any companies or products mentioned in this article /15/ /$18.00/0 Journal of Reproductive Medicine, Inc. The Journal of Reproductive Medicine 463
2 464 The Journal of Reproductive Medicine trolled ovarian hyperstimulation, estradiol, GnRH, gonadotropin-releasing hormone, in vitro intracytoplasmic sperm injection, fertilization, live birth, miscarriage, ovarian hyperstimulation syndrome, pregnancy outcome, spontaneous abortion. Ovarian hyperstimulation syndrome (OHSS) is a well-recognized and potentially fatal iatrogenic complication of controlled ovarian hyperstimulation (COH) during in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) cycles. While its true incidence is probably vastly underestimated due to inconsistent reporting, a protocol development has arisen in the past decade allowing for a paradigm shift in the treatment of high-risk patients and a virtual elimination of this serious complication. 1 Triggering the induction of final oocyte maturation with a gonadotropin-releasing hormone agonist (GnRHa) instead of human chorionic gonadotropin (hcg) was first proposed over 20 years ago as a means to decrease the burden of OHSS. 2 While it achieves this end with great efficiency, subsequent studies demonstrated poorer pregnancy outcomes attributable to defective hormone production from GnRHa-induced luteolysis. 3-5 However, as a subject of significant investigative interest during the past several years, newer studies promoting further protocol changes have brought about greatly improved pregnancy outcomes while maintaining a very low incidence of OHSS. These include the addition of low-dose hcg, either at the time of GnRHa trigger ( dual trigger ) or on the day of oocyte retrieval, more intensive luteal phase supplementation (LPS) with estradiol (E2) and progesterone (P), and the planned cryopreservation of all embryos for transfer in a programmed cycle As a result, clinicians have become more comfortable using GnRHa trigger, now able to worry less about OHSS and impaired pregnancy rates. The association between the supraphysiologic hormone milieu of COH, endometrial receptivity, and pregnancy outcomes is another area of recent investigative interest. Most studies appear to find detriment with high hormone levels There is, however, little known about what stimulation parameters, if any, are important predictors in GnRHa-triggered cycles. One such study reported clinical outcomes to be related to luteinizing hormone (LH) level on the day of trigger and even improved in cycles with peak E2 >4,000 pg/ml. 22 In light of such conflicting data, we sought to attempt to elucidate what factors can be useful as clinical determinants in high responders undergoing IVF/ICSI cycles using a GnRHa trigger. This patient population, by definition, is predisposed to excessive hormone profiles during COH. If, indeed, defective endometrial receptivity results from high E2 levels in fresh cycles, patients triggered with a GnRHa, given their propensity for a high response, may be quietly in danger of a worse prognosis than would otherwise be expected. Materials and Methods Study Design and Participants This was a retrospective cohort study conducted at the Duke Fertility Center. Study approval was granted by the Duke University Institutional Review Board. The records of all patients who underwent fresh, autologous, IVF/ICSI using a GnRH antagonist protocol and a GnRHa trigger for oocyte maturation from January 2010 to December 2012 were reviewed. Seventy-one first cycles were included for analysis. All patients were deemed high risk for OHSS based on age, ovarian reserve testing, peak serum E2, and/or >13 follicles measuring >11 mm in diameter on the day of trigger. 23 Treatment Protocol The treatment and LPS protocols used were previously described by Engmann et al. 12 Baseline transvaginal ultrasound was performed following 2 3 weeks of oral contraceptive pill suppression. On menstrual cycle day 1 2, a daily subcutaneous injection of recombinant follicle stimulating hormone (rfsh) (Follistim, Merck, Whitehouse Station, New Jersey) was initiated. The usual starting dose of IU was based on patient age, body mass index, antral follicle count, and anti-müllerian hormone level (available in 63/71 patients). Serial ultrasounds and serum E2 measurements were performed to assess response to stimulation and adjust medication dose at the discretion of the treating physician. When the lead follicle reached a mean diameter of 13 mm and/or the serum E2 exceeded 350 pg/ml, a daily subcutaneous injection of 250 µg of the GnRH antagonist ganirelix acetate (Ganirelix, Merck) was added to prevent premature ovulation. These were continued until the day of oocyte maturation induction. When 3 follicles reached 17 mm in mean diameter, 1 mg of leuprolide acetate (Lupron, TAP Pharmaceuticals, Lake Forest, Illinois) was administered subcutaneously between 8 and 10 o clock in the evening. Serum
3 Volume 60, Number 11-12/November-December E2, LH, and P levels were measured the following morning to ensure adequate surge. Transvaginal, ultrasound-guided oocyte retrieval was performed approximately 36 hours after trigger injection. Luteal Phase Supplementation All patients received 50 mg intramuscular (IM) P in oil daily and 0.3 mg E2 patches (Vivelle-Dot, Novartis Pharmaceuticals, East Hanover, New Jersey) every other day beginning on the day after oocyte retrieval and continuing until either 10 weeks of gestation or a negative pregnancy test. Serum E2 and P were measured 3 and 7 days after oocyte retrieval and then weekly until 10 weeks of gestation. To maintain serum E2 above 200 pg/ml, either patches were increased up to 0.4 mg every other day or 2 mg of twice-daily oral, micronized E2 (Estrace, Bristol-Meyers, New York, New York) was added, as necessary. Similarly, IM P was increased to 75 mg daily, as needed, to keep serum levels above 20 ng/ml. 24 Outcome Variables The primary outcome was live birth (LB). Secondary outcomes included rates of clinical pregnancy (CP), clinical miscarriage (MC), total MC, and moderate to severe OHSS. Clinical pregnancy was defined as the presence of an intrauterine gestational sac (GS) at 6 7 weeks gestation coincident with a rising serum β-hcg level. Clinical MC was defined as pregnancy loss after ultrasound visualization of an intrauterine GS. Total MC included clinical plus biochemical MC, the latter defined as pregnancy loss prior to ultrasound identification of a GS. Data Analysis The SAS statistical package (Release 9.3, SAS Institute, Cary, North Carolina) was used for statistical analysis. Summary statistics for baseline and cycle variables were computed and are presented as means (standard deviation [SD]). Univariable analysis to compare the equivalence of each clinical variable between outcome statuses was performed using two-sample t tests for continuous variables and χ 2 tests for categorical variables. Multiple logistic regression modeling was performed for each variable of interest with covariate adjustment for patient age, basal FSH, and the number of oocytes retrieved. Estimated odds ratios (ORs) and their 95% confidence intervals (CIs) are reported. A nominal significance level (p<0.05) was used to declare statistical significance. Results Baseline and cycle variables are shown in Table I. The mean age was 33.4 years. The average anti- Müllerian hormone level and antral follicle count were 5.0 ng/ml and 21.2, respectively. All patients demonstrated adequate surge after trigger. The rates of CP, clinical MC, total MC, and LB were 52.1%, 14.1%, 25.4%, and 38%, respectively. The rate of twin gestation was 15.5%, and none of these pregnancies ended in miscarriage. There were no cases of high-order multiples or OHSS. The mean peak E2 and number of oocytes Table I Baseline and Cycle Variables Variable N Mean (SD) Minimum Maximum Age (yrs) (3.94) BMI (kg/m 2 ) (6.72) AMH (ng/ml) (3.59) AFC (n) (10.39) 3 51 D3 FSH (miu/ml) (1.99) Days of stimulation (n) (1.46) 7 14 Peak E2 (pg/ml) 69 3, (1,669.47) 1,042 7,208 Posttrigger P4 (ng/ml) (4.91) Posttrigger LH (IU/L) (20.62) Oocytes retrieved (n) (6.90) PN (n) (4.34) 1 28 Cleaved (n) (4.27) 1 28 Transferred (n) (0.43) 1 3 Cryopreserved (n) (4.20) 0 26 BMI = body mass index, AMH = anti-müllerian hormone, AFC = antral follicle count, D3 FSH = day 3 follicle stimulating hormone, E2 = estradiol, posttrigger P4 = progesterone on day after trigger, posttrigger LH = luteinizing hormone on day after trigger, 2PN = two pronuclear zygote.
4 466 The Journal of Reproductive Medicine retrieved were 3,701 pg/ml and 15.2, respectively. Pregnancy outcomes per peak E2 level for the entire cohort are shown in Table II. While not statistically significant, peak E2 was lower in pregnancies resulting in LB. It was, however, significantly higher in those resulting in clinical MC (p=0.003). Post-trigger LH and P4 were not related to the investigated outcomes (Table III). After adjusting for age, basal FSH, and the number of oocytes retrieved in the multiple logistic regression model, peak E2 remained associated with increased clinical MC (p=0.029) (Table III) and trended towards a relationship with higher total MC (p=0.062). We then examined the frequency of clinical MC for each 1,000 pg/ml peak E2 interval (Figure 1). Due to the abrupt increase in clinical MC above 5,000 pg/ml, we chose this value as the threshold around which to dichotomize the data (peak E2 status). That is, clinical MC rate ranged from approximately 6 14% in each of the five 1,000 pg/ml groups below 5,000 pg/ml but increased to 33% (5/15 patients) when peak E2 reached 5,000 pg/ ml. Once again controlling for age, basal FSH, and the number of oocytes retrieved, peak E2 5,000 pg/ml was associated with significantly higher rates of clinical MC (OR with 95% CI , p=0.033) and total MC (OR 6.81 with 95% CI , p=0.037), as well as fewer LBs (OR with 95% CI , p=0.041) (Table IV). Discussion Our findings demonstrate that extremely supraphysiologic E2 levels appear to be associated with worse pregnancy outcomes in fresh, autologous, GnRH antagonist IVF/ICSI cycles when using a GnRHa trigger. After adjusting for confounders, fewer LBs and more MCs were observed with elevated peak E2, especially when it exceeded 5,000 pg/ml. These results contribute to a recent focus in the literature attempting to clarify defective en- dometrial receptivity from supraphysiologic hormone levels in fresh cycles as the causative mechanism for poorer obstetric outcomes. Indeed this association may be even more pronounced in cycles using a GnRHa trigger, owing to the added corpora lutea (CL) dysfunction from the agonist, and there is currently a paucity of literature on the combination of these two topics. Our study suggests that, similar to IVF/ICSI cycles using hcg trigger, optimal pregnancy outcomes are achieved in GnRHatriggered cycles either by avoiding excessively high E2 levels during fresh cycles or by cryopreserving all embryos for subsequent frozen embryo transfer (FET). Moreover, it seems imperative to recognize this cohort of patients as inherently at risk for this scenario given their tendency for high response. hcg has historically been the therapeutic means to replace endogenous LH to induce oocyte maturation and ovulation in IVF/ICSI cycles. Due to their similar structure and biological activity, hcg and LH act on the same receptor. 25 However, the half-life of LH is approximately 60 minutes, whereas that of hcg is >24 hours. 26,27 Thus, hcg produces a much more sustained effect on the CL, predisposing normal and high responders to a greater risk of OHSS. Specifically, LH receptor stimulation on the ovarian theca cells stimulates production of androstenedione, which then diffuses into the granulosa cells and serves as the primary precursor for E2 production. It is the exaggeration of this process, particularly in high responders, that contributes to the pathogenesis of OHSS and altered endometrial receptivity. With the advent of GnRH antagonist protocols in the late 1990s it became possible to induce oocyte maturation with a GnRHa. Doing so causes an initial surge of LH and FSH followed by pituitary suppression with continued use. But the rise and fall of this flare is much more abbreviated than in a natural cycle, and thus the total amount of gonadotropin released from the pituitary after Table II Pregnancy Outcomes per Peak Estradiol Level Peak estradiol (pg/ml) <2,000 2,000 3,000 3,000 4,000 4,000 5,000 >5,000 Outcome n=12 n=17 n=14 n=11 n=17 + Pregnancy test (%) Clinical pregnancy (%) Live birth (%) Miscarriage (%)
5 Volume 60, Number 11-12/November-December Table III Comparison of Hormone Variables Between Pregnancy Outcomes Live birth Mean (SD) Clinical miscarriage Mean (SD) Category (N) LB (27) No LB (44) P a P b CM (10) No CM (61) P a P b Peak E2 (pg/ml) 3,310 (1,998) 3,952 (1,956) ,218 (1,879) 3,473 (1,526) Posttrigger LH (IU/L) 38.8 (21.3) 37.1 (20.4) (17.1) 37.9 (21.2) Posttrigger P4 (ng/ml) 10.3 (5.9) 9.3 (4.2) (3.8) 9.6 (5.1) SD = standard deviation, E2 = estradiol, LH = luteinizing hormone, P4 = progesterone. a p values derived from t test. b p values derived from multivariate logistic regression which adjusted for age, basal FSH, and the number of oocytes retrieved. GnRHa is significantly less. 1,28 One potential benefit of GnRHa trigger, however, is the simultaneous release of FSH, akin to the natural cycle. 3 FSH has been shown to induce LH receptor formation on granulosa cells and promote nuclear maturation and cumulus expansion, which may explain why some studies using GnRHa trigger have reported a significantly higher number of mature oocytes compared to hcg trigger. 4,33 In 1988 Itskovitz was the first to propose the use of GnRHa for oocyte maturation as a way to decrease the incidence of OHSS in IVF cycles. 2 In the past decade over a dozen randomized controlled trials (RCTs) have proven the efficacy of GnRHa in eliminating OHSS. 1 As alluded to above, during the same time period multiple welldesigned studies demonstrated no difference, or even an increase, in the rate of metaphase II oocytes, as well as no detriment to fertilization or embryo quality with GnRHa trigger. 3-5,34 Despite these apparent accomplishments, widespread use of GnRHa trigger has been met with resistance, largely due to several initial reports of poorer implantation, lower ongoing pregnancy rates, and higher pregnancy loss rates in normal responders using standard LPS. 3-5 However, subsequent RCTs investigating normal and high responders showed no difference in LB rates, while maintaining very low OHSS rates, with the addition of one or multiple smaller doses of hcg or recombinant LH (rlh) added at the time of trigger and/or oocyte retrieval in order to augment oocyte maturation or luteal phase hormone production, respectively Additionally, despite the fact that one small study 8 found disparate results, a 2008 RCT demonstrated similar LB rates between GnRHa and hcg trigger in high responders with only the addition of more aggressive luteal E2 and P supplementation. 12 Taken all together, it seems that overcoming the luteolytic property of the GnRHa, one way or another, is key to preserving pregnancy potential after GnRHa trigger in autologous, fresh cycles. Current recommendations from the Copenhagen GnRH Agonist Triggering Workshop Group expand upon this idea as they make recommendations for the use of GnRHa trigger in several patient populations. 1 According to their 2011 publication, for all patients, good oocyte quality can be achieved with GnRHa trigger while practically eradicating the risk of OHSS. They advocate its universal use in oocyte donors, highlighting the added benefits of a shorter luteal phase and reduction in ovarian size and pelvic free fluid after oocyte retrieval. Finally, while the optimal LPS regimen is yet to be fully elucidated, ongoing pregnancy rates similar to hcg trigger can be achieved in one of two ways: (1) by adding one or more injections of low-dose hcg or rlh at the time of trigger ( dual trigger ) and/or in the luteal phase, in addition to modified E2 and P4 supplementation, or (2) by freezing all embryos and transferring them after thaw in a subsequent programmed cycle. 1 Figure 1 Clinical miscarriage frequency per 1,000 pg/ml peak E2 interval. CM = clinical miscarriage, E2 = estradiol.
6 468 The Journal of Reproductive Medicine At present, the relationship between the supraphysiologic hormonal milieu of fresh IVF cycles and endometrial receptivity continues to be debated. Many investigators have examined the issue over the past 25 years. Despite an assortment of differing study designs and populations that ultimately make definitive conclusions elusive, when considered collectively, the data seem to suggest an adverse endometrial effect of very elevated E2. Forman et al demonstrated significantly lower implantation and pregnancy rates in cycles with high E2. 13 Simon et al faulted altered endometrial receptivity after similar findings in normal and high responders with peak E2 >2,500 pg/ml, despite no difference in oocyte number or embryo quality. 14 Another study by the same author concluded improved receptivity in high responders by using an rfsh step-down protocol to achieve a lower peak E2. 15 Similar conclusions were drawn from two studies that found inferior pregnancy rates in fresh but not in frozen/thaw cycles when peak E2 exceeded 5,000 pg/ml. 16,17 A 2010 study of 455 fresh IVF cycles using hcg trigger suggested an optimal peak E2 threshold of 4,000 pg/ ml for women <38 years of age and 3,000 pg/ml for those Moreover, endometrial gene expression, including that for E2 and P receptors, has been shown to be significantly altered in stimulated cycles, indicating a state of premature endometrial advancement compared to natural cycles Perhaps the most compelling evidence in support of the notion of defective endometrial receptivity associated with supraphysiologic hormone levels in stimulated cycles is the growing number of studies showing better outcomes in freeze-all/ thaw cycles. In separate RCTs investigating normal and high responders, Shapiro et al demonstrated improved clinical and ongoing pregnancy rates after elective FET. 35,36 In another elegant study from the same group, 93 pairs of fresh and frozen/thawed blastocysts were matched on embryo parameters and patient age. 37 Single blastocyst transfer revealed a significantly better PR in the frozen/thaw group for day-6 blasts (54.3% vs. 17.1% in the fresh group, p<0.001). This resulted in a significantly higher ongoing PR in the frozen/ thaw group as compared to the fresh (55.9% vs. 26.9%, respectively, p<0.001). The authors point toward impaired embryo implantation from altered endometrial receptivity in the setting of recent ovarian stimulation. They highlight their findings as support for embryo-endometrium asynchrony since the more slowly-developing blasts (day 6) appeared to be most affected; i.e., the slowergrowing embryos may miss a more advanced or narrow implantation window after recent COS. Finally, the theory of impaired endometrial receptivity has gone so far as to surface in literature regarding obstetric and perinatal outcomes. A 2012 metaanalysis of 11 observational studies comparing singleton pregnancies in fresh versus frozen/ thaw cycles demonstrated better outcomes in the latter group. 38 These include significantly lower relative risks of antepartum hemorrhage, preterm birth, small-for-gestational-age infants, low birth weight, and perinatal mortality. Once again, the authors postulate that very high steroid hormone levels during COH result in endometrial advancement causing asynchrony with early embryo development that ultimately leads to abnormal placentation that contributes to these complications. The results of the present study support a role for altered endometrial receptivity to explain poorer pregnancy outcomes in high responders whose cycles have resulted in very high peak E2 levels. Weaknesses of the study include its retrospective design and small sample size. Therefore, estimates of the outcomes of interest are based on relatively few observations, and type 1 error cannot be excluded. Furthermore, CP, LB, and MC, despite being clinically significant outcomes, are statistically correlated. By repeating them in a multivariate analysis, we cannot exclude the possibility of finding associations by chance. In addition, selection bias may exist from heterogeneity in medication dosing and patient diagnosis (for example, the cohort included some patients with polycystic ovary syndrome). However, our inclusion of only GnRH antagonist cycles using a GnRHa for oocyte maturation makes our findings unique to the vast majority of published data on the subject and draws attention to a particularly vulnerable subgroup of patients. In an era when comfort with GnRHa trigger is becoming more common thanks to improvements in LPS, including the use of dual trigger, the continuing trend of evidence linking the supraphysiologic hormone milieu of COH to impaired endometrial receptivity deserves added reflection. The use of GnRHa trigger itself, in fresh, autologous cycles, should probably serve as an immediate red flag because it identifies those patients most likely to demonstrate an exaggerated response to stimulation. With the realization that the inci-
7 Volume 60, Number 11-12/November-December Table IV Results of Multivariate Logistic Regression Analysis for Each Clinical Outcome Using Dichotomized Peak E2 Status (>5,000 pg/ ml Compared to <5,000 pg/ml), with Adjusted Covariates Peak E2 status Covariates (p value) Outcome OR 95% CI p Value Age D3 FSH Oocytes retrieved Clinical pregnancy Clinical miscarriage Total miscarriage Live birth OR = odds ratio. dence of moderate to severe OHSS after GnRHa trigger is extremely low, less importance is often placed on peak E2. That is, agonist trigger prevents OHSS even with extremely high E2 levels. Thus, it becomes easy to aggressively stimulate patients with less regard to rising E2, knowing the agonist trigger is such an effective guarantee against OHSS. In this way, the attempt to prevent one ill effect directly opens the door for another. Our findings suggest that such a practice is a mistake. The importance of this observation may be further underestimated when one considers the luteolytic property of the agonist, as it seems plausible that this may have an additive negative effect on endometrial receptivity. The detriment from embryo/endometrium asynchrony due to high hormone levels may be compounded by deficient E2 and P production from the CL, creating an even more fragile environment for proper implantation. In conclusion, very high levels of peak E2 in high responders triggered with a GnRHa should be avoided to maximize endometrial receptivity and improve pregnancy outcomes, irrespective of OHSS prevention. Clinicians should recognize this patient population as inherently in danger of this scenario and minimize the occurrence of peak E2 levels >5,000 pg/ml. Well-designed, prospective trials are needed to shed further light on the concept of endometrial receptivity in IVF/ICSI cycles using a GnRHa trigger. Acknowledgments The authors would like to thank the Duke Fertility Center staff for their support in generating this manuscript. References 1. Humaidan P, Kol S, Papanikolaou EG: GnRH agonist for triggering of final oocyte maturation: Time for a change of practice? Hum Reprod 2011;17: Itskovitz J, Boldes R, Barlev A, et al: The induction of LH surge and oocyte maturation by GnRH analogue (buserelin) in women undergoing ovarian stimulation for in vitro fertilization. Gynecol Endocrinol 1988;2(Suppl 2): Fauser BC, de Jong D, Olivennes F, et al: Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization. J Clin Endocrinol Metab 2002;87: Humaidan P, Bredkjaer HE, Bungum L, et al: GnRH agonist (buserelin) or hcg for ovulation induction in GnRH antagonist IVF/ICSI cycles: A prospective randomized study. Hum Reprod 2005;20: Kolibianakis EM, Schultze-Mosgau A, Schroer A, et al: A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists. Hum Reprod 2005;20: Humaidan P, Bungum L, Bungum M, et al: Rescue of corpus luteum function with peri-ovulatory HCG supplementation in IVF/ICSI GnRH antagonist cycles in which ovulation was triggered with a GnRH agonist: A pilot study. Reprod Biomed Online 2006;13: Humaidan P, Ejdrup Bredkjaer H, Westergaard LG, et al: 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: A prospective, randomized, controlled study. Fertil Steril 2010;93: Pirard C, Donnez J, Loumaye E: GnRH agonist as luteal phase support in assisted reproduction technique cycles: Results of a pilot study. Hum Reprod 2006;21: Acevedo B, Gomez-Palomares JL, Ricciarelli E, et al: Triggering ovulation with gonadotropin-releasing hormone agonists does not compromise embryo implantation rates. Fertil Steril 2006;86: Castillo JC, Dolz M, Bienvenido E, et al: Cycles triggered with GnRH agonist: Exploring low-dose HCG for luteal support. Reprod Biomed Online 2010;20: Papanikolaou EG, Verpoest W, Fatemi H, et al: A novel method of luteal supplementation with recombinant LH, when a GnRH-agonist is used instead of HCG for ovulation triggering: A randomized prospective proof of concept study. Fertil Steril 2011;3: Engmann L, DiLuigi A, Schmidt D, et al: The use of gonadotropinreleasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: A prospective randomized controlled study. Fertil Steril 2008;89: Forman R, Fries N, Testart J, et al: Evidence for an adverse effect of elevated serum estradiol concentrations on embryo implantation. Fertil Steril 1988;49: Simon C, Coro F, Valbuena D, et al: Clinical evidence for a detrimental effect on uterine receptivity of high serum oestradiol concentrations in high and normal responder patients. Hum Reprod 1995;10:
8 470 The Journal of Reproductive Medicine 15. Simon C, Garcia Velasco JI, Valbuena D, et al: Increasing uterine receptivity by decreasing oestradiol levels during the preimplantation period in high responders with the use of a follicle stimulating hormone step-down regimen. Fertil Steril 1998;70: Ng EH: What is the threshold value for serum estradiol levels associated with adverse IVF outcomes? Fertil Steril 2000;73: Wu C-H, Kuo T-C, Wu H-H, et al: High serum estradiol levels are not detrimental to in vitro fertilization outcome. Taiwan J Obstet Gynecol 2007;46: Joo BS, Park SH, An BM, et al: Serum estradiol levels during controlled ovarian hyperstimulation influence the pregnancy outcome of in vitro fertilization in a concentration-dependent manner. Fertil Steril 2010;93: Groothuis PG, Dassen HH, Romano A, et al: Estrogen and the endometrium: Lessons learned from gene expression profiling in rodents and human. Hum Reprod Update 2007;13: Haouzi D, Assou S, Mahmoud K, et al: Gene expression profile of human endometrial receptivity: Comparison between natural and stimulated cycles for the same patients. Hum Reprod 2009;24: Papanikolaou EG, Bourgain C, Kolibianakis E, et al: Steroid receptor expression in late follicular phase endometrium in GnRH antagonist IVF cycles is already altered, indicating initiation of early luteal phase transformation in the absence of secretory changes. Hum Reprod Update 2005;20: Kummer N, Benadiva C, Feinn R, et al: Factors that predict the probability of successful clinical outcome after induction of oocyte maturation with a gonadotropin-releasing hormone agonist. Fertil Steril 2011;96: Papanikolaou EG, Pozzobon C, Kolibianakis EM, et al: Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles. Fertil Steril 2006;85: Rosenwaks Z: Donor eggs: Their application in modern reproductive technologies. Fertil Steril 1987;47: Kessler MJ, Reddy MS, Shah RH, et al: Structures of N-glycosidic carbohydrate units of human chorionic gonadotropin. J Biol Chem 1979; 254: Yen SS, Llerena O, Little B, et al: Disappearance rates of endogenous luteinizing hormone and chorionic gonadotropin in man. J Clin Endocrinol Metab 1968;28: Damewood MD, Shen W, Zacur HA, et al: Disappearance of exogenously administered human chorionic gonadotropin. Fertil Steril 1989;52: Itskovitz J, Boldes R, Levron J, et al: Induction of preovulatory luteinizing hormone surge and prevention of ovarian hyperstimulation syndrome by gonadotropin-releasing hormone agonist. Fertil Steril 1991;56: Zelinski-Wooten MB, Hutchison JS, Hess DL, et al: Follicle stimulating hormone alone supports follicle growth and oocyte development in gonadotropin-releasing hormone antagonist-treated monkeys. Hum Reprod 1995;10: Yding Andersen C, Leonardsen L, Ulloa-Aguirre A, et al: FSHinduced resumption of meiosis in mouse oocytes: Effect of different isoforms. Mol Hum Reprod 1999;5: Stickland S, Beers WH: Studies on the role of plasminogen activator in ovulation: In vitro response of granulosa cells to gonadotropins, cyclic nucleotides, and prostaglandins. J Biol Chem 1976;251: Eppig JJ: FSH stimulates hyaluronic acid synthesis by oocytecumulus cell complexes from mouse preovulatory follicles. Nature 1979;281: Oktay K, Turkcuoglu I, Rodriguez-Wallberg KA: GnRH agonist trigger for women with breast cancer undergoing fertility preservation by aromatase inhibitor/fsh stimulation. Reprod Biomed Online 2010;20: Griesinger G, Diedrich K, Devroey P, et al: GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: A systematic review and meta-analysis. Hum Reprod Update 2006;12: Shapiro BS, Daneshmand ST, Garner FC, et al: Evidence of impaired endometrial receptivity after ovarian stimulation for in vitro fertilization: A prospective randomized trial comparing fresh and frozenthawed embryo transfer in normal responders. Fertil Steril 2011;96: Shapiro BS, Daneshmand ST, Garner FC, et al: Evidence of impaired endometrial receptivity after ovarian stimulation for in vitro fertilization: A prospective randomized trial comparing fresh and frozenthawed embryo transfers in high responders. Fertil Steril 2011;96: Shapiro BS, Daneshmand ST, Restrepo H, et al: Matched-cohort comparison of single-embryo transfers in fresh and frozen-thawed embryo transfer cycles. Fertil Steril 2013;99: Maheshwari A, Pandey S, Shetty A, et al: Obstetric and perinatal outcomes in singleton pregnancies resulting from the transfer of frozen thawed versus fresh embryos generated through in vitro fertilization treatment: A systematic review and meta-analysis. Fertil Steril 2012;98:
Luteal phase rescue after GnRHa triggering Progesterone and Estradiol
Luteal phase rescue after GnRHa triggering Progesterone and Estradiol L. Engmann University of Connecticut Disclaimer Fertility Speaker Bureau Merck Pharmaceuticals Introduction GnRH agonist is effective
More informationSredišnja medicinska knjižnica
Središnja medicinska knjižnica Kasum M., Kurdija K., Orešković S., Čehić E., Pavičić-Baldani D., Škrgatić L. (2016) Combined ovulation triggering with GnRH agonist and hcg in IVF patients. Gynecological
More informationAOGS COMMENTARY SHAHAR KOL 1, ROY HOMBURG 2,3, BIRGIT ALSBJERG 4 & PETER HUMAIDAN 5. Abstract
A C TA Obstetricia et Gynecologica AOGS COMMENTARY The gonadotropin-releasing hormone antagonist protocol the protocol of choice for the polycystic ovary syndrome patient undergoing controlled ovarian
More informationA rationale for timing of luteal support post GnRH agonist trigger. Address: IVF Unit, Elisha Hospital, 12 Yair Katz Street, Haifa, Israel,
Short Review: A rationale for timing of luteal support post GnRH agonist trigger Shahar Kol, IVF Unit, Elisha Hospital, Haifa, Israel. Address: IVF Unit, Elisha Hospital, 12 Yair Katz Street, Haifa, Israel,
More informationProgesterone and clinical outcomes
Synchronization of Slowly Developing Embryos Restores Implantation Success Richard T. Scott, Jr, MD, HCLD Clinical and Scientific Director, Reproductive Medicine Associates of New Jersey Professor and
More informationLOW RESPONDERS. Poor Ovarian Response, Por
LOW RESPONDERS Poor Ovarian Response, Por Patients with a low number of retrieved oocytes despite adequate ovarian stimulation during fertility treatment. Diagnosis Female About Low responders In patients
More informationA Tale of Three Hormones: hcg, Progesterone and AMH
A Tale of Three Hormones: hcg, Progesterone and AMH Download the Ferring AR ipad/iphone app from the Apple Store: http://bit.ly/1okk74m Interpreting Follicular Phase Progesterone Ernesto Bosch IVI Valencia,
More informationOriginal Article Impact of estrogen-to-oocyte ratio on live birth rate in women undergoing in vitro fertilization and embryo transfer
Int J Clin Exp Med 2015;8(7):11327-11331 www.ijcem.com /ISSN:1940-5901/IJCEM0008838 Original Article Impact of estrogen-to-oocyte ratio on live birth rate in women undergoing in vitro fertilization and
More informationLUTEAL PHASE SUPPORT. Doç. Dr. Nafiye Yılmaz. Zekai Tahir Burak Kadın Sağlığı Eğitim Araştırma Hastanesi
LUTEAL PHASE SUPPORT Doç. Dr. Nafiye Yılmaz Zekai Tahir Burak Kadın Sağlığı Eğitim Araştırma Hastanesi TAJEV, 2014 1 ART & success *Live birth rate 2 Optimal luteal phase Etiology of luteal phase deficiency
More informationUniversal Embryo Cryopreservation: Frozen versus Fresh Transfer. Zaher Merhi, M.D.
Universal Embryo Cryopreservation: Frozen versus Fresh Transfer Zaher Merhi, M.D. Disclosure: None Fewer complications with IVF 1.5% children in US are born through ART 1.1 million children since 2006
More informationHow to make the best use of the natural cycle for frozen-thawed embryo transfer?
How to make the best use of the natural cycle for frozen-thawed embryo transfer? Ariel Weissman, MD IVF Unit, Dep. Ob/Gyn Wolfson Medical Center, Holon Sackler Faculty of Medicine, Tel Aviv University
More informationInterpreting follicular Progesterone: Late follicular Progesterone to Estradiol ratio is not influenced by protocols or gonadotropins used
Interpreting follicular Progesterone: Late follicular Progesterone to Estradiol ratio is not influenced by protocols or gonadotropins used Ellenbogen A., M.D., Shalom-Paz E., M.D, Asalih N., M.D, Samara
More informationShi-Ling Chen*,, De-Sheng Ye, Xin Chen, Xin-Hong Yang, Hai-Yan Zheng, Yan Tang, Yu-Xia He, and Wei Guo
Human Reproduction, Vol.27, No.5 pp. 1351 1356, 2012 Advanced Access publication on March 14, 2012 doi:10.1093/humrep/des049 ORIGINAL ARTICLE Infertility Circulating luteinizing hormone level after triggering
More informationOvarian hyperstimulation syndrome- an optimal solution for an unresolved enigma
Orvieto Journal of Ovarian Research 2013, 6:77 REVIEW Open Access Ovarian hyperstimulation syndrome- an optimal solution for an unresolved enigma Raoul Orvieto 1,2 Abstract Ovarian hyperstimulation syndrome
More informationClinical Study Clinical Effects of a Natural Extract of Urinary Human Menopausal Gonadotrophin in Normogonadotropic Infertile Patients
International Reproductive Medicine Volume 2013, Article ID 135258, 4 pages http://dx.doi.org/10.1155/2013/135258 Clinical Study Clinical Effects of a Natural Extract of Urinary Human Menopausal Gonadotrophin
More informationComparison of GnRH agonist with low-dose urinary hcg for induction of final oocyte maturation
Basrah Journal Of Surgery COMPARISON OF GNRH AGONIST WITH LOW-DOSE URINARY HCG FOR THE INDUCTION OF FINAL OOCYTE MATURATION IN HIGH-RISK PATIENTS UNDERGOING INTRACYTOPLASMIC SPERM INJECTION-EMBRYO TRANSFER
More informationRaoul Orvieto. The Chaim Sheba Medical Center Tel Hashomer, Israel. Declared no potential conflict of interest
Raoul Orvieto The Chaim Sheba Medical Center Tel Hashomer, Israel Declared no potential conflict of interest LH in antagonist cycles; is the story really written? Raoul Orvieto M.D. Israel Overview Role
More informationPrinciples of Ovarian Stimulation
Principles of Ovarian Stimulation Dr Genia Rozen Gynaecologist and Fertility Specialist Royal Women s Hospital and Melbourne IVF Learning objectives Why ovarian stimulation Recap physiology Ovarian cycle
More informationIVF (,, ) : (HP-hMG) - (IVF- ET) : GnRH, HP-hMG (HP-hMG )57, (rfsh )140, (Gn)
34 11 Vol.34 No.11 2014 11 Nov. 2014 Reproduction & Contraception doi: 10.7669/j.issn.0253-3X.2014.11.0892 E-mail: randc_journal@163.com IVF ( 710003) : (H-hMG) - (IVF- ET) : GnRH H-hMG (H-hMG ) (rfsh
More informationIVF Protocols: Hyper & Hypo-Responders, Implantation
IVF Protocols: Hyper & Hypo-Responders, Implantation Midwest Reproductive Symposium June 4-5, 4 2010 Subset : Hyper-Responders Mark R. Bush, MD, FACOG, FACS OBJECTIVE: Important goals for the PCOS patient
More informationSTIMULATION AND OVULATION TRIGGERING
STIMULATION AND OVULATION TRIGGERING Professor IOANNIS E. MESSINIS MD, PhD (Aberdeen, UK), FRCOG (UK) Department of Obs/Gynae University of Thessaly Larissa, GREECE DISCLOSURE Nothing to disclose Learning
More informationOvarian hyperstimulation syndrome (OHSS)
Ovarian hyperstimulation syndrome (OHSS) OHSS OHSS: exaggerated response to gonadotropins and hcg Characterized by: ovarian enlargement increased vascular permeability fluid accumulation in abdomen Associated
More informationThe serum estradiol/oocyte ratio in patients with breast cancer undergoing ovarian stimulation with letrozole and gonadotropins
Original Article Obstet Gynecol Sci 2018;61(2):242-246 https://doi.org/10.5468/ogs.2018.61.2.242 pissn 2287-8572 eissn 2287-8580 The serum estradiol/oocyte ratio in patients with breast cancer undergoing
More informationMenstruation-free interval and ongoing pregnancy in IVF using GnRH antagonists
Human Reproduction Vol.21, No.4 pp. 1012 1017, 2006 Advance Access publication December 8, 2005. doi:10.1093/humrep/dei415 Menstruation-free interval and ongoing pregnancy in IVF using GnRH antagonists
More informationInfertility Clinical Guideline
Infertility Clinical Guideline Ovarian Stimulation Guideline Purpose: To provide sufficient background regarding various ovarian stimulation protocols for In Vitro Fertilization cycles. Goal: To assist
More informationArticle Luteal hormonal profile of oocyte donors stimulated with a GnRH antagonist compared with natural cycles
RBMOnline - Vol 13. No 3. 2006 326 330 Reproductive BioMedicine Online; www.rbmonline.com/article/1911 on web 13 June 2006 Article Luteal hormonal profile of oocyte donors stimulated with a GnRH antagonist
More informationHow to make the best use of the natural cycle for frozen-thawed embryo transfer?
How to make the best use of the natural cycle for frozen-thawed embryo transfer? Ariel Weissman, MD IVF Unit, Dep. Ob/Gyn Wolfson Medical Center, Holon Sackler Faculty of Medicine, Tel Aviv University
More information2013 Sep.; 24(3):
Journal of Reproduction & Contraception doi: 10.7669/j.issn.1001-7844.2013.03.0151 2013 Sep.; 24(3):151-158 E-mail: randc_journal@163.com Reducing the Trigger Dose of Human Chorionic Gonadotrophin Does
More informationGnRH agonist triggering: recent developments
Reproductive BioMedicine Online (2013) 26, 226 230 www.sciencedirect.com www.rbmonline.com REVIEW GnRH agonist triggering: recent developments Shahar Kol a, *, Peter Humaidan b a Department of Obstetrics
More informationMilder is better? Advantages and disadvantages of "mild" ovarian stimulation for human in vitro fertilization
Milder is better? Advantages and disadvantages of "mild" ovarian stimulation for human in vitro fertilization Revelli et al. Reproductive Biology and Endocrinology 2011, 9:25 Presenter: R2 孫怡虹 Background
More informationPoor & Hyper responders: what is the best approach?
Poor & Hyper responders: what is the best approach? A. La Marca ObGyn Dept University of Modena and Reggio Emilia Italy Center for Reproductive Medicine University Hospital of Modena Italy Criteria used
More informationREstradiol and Antagonist Pretreatment Prior to Microdose Leuprolide in in Vitro Fertilization
REstradiol and Antagonist Pretreatment Prior to Microdose Leuprolide in in Vitro Fertilization Does It Improve IVF Outcomes in Poor Responders as Compared to Oral Contraceptive Pill? FTThe Journal of Reproductive
More informationBest practices of ASRM and ESHRE
Best practices of ASRM and ESHRE Late submission Cortina d Ampezzo, Italy 1-3 March 2012 A joint meeting between the American Society for Reproductive Medicine and the European Society of Human Reproduction
More informationMaria A. Manzanares, M.D., Jose Lui Gomez-Palomares, M.D., Elisabetta Ricciarelli, M.D., and Eleuterio R. Hernandez, M.D., Ph.D.
Triggering ovulation with gonadotropin-releasing hormone agonist in in vitro fertilization patients with polycystic ovaries does not cause ovarian hyperstimulation syndrome despite very high estradiol
More informationAdvanced age, poor responders and the role of LH supplementation. C. Alviggi University Federico II, Naples, Italy
Advanced age, poor responders and the role of LH supplementation C. Alviggi University Federico II, Naples, Italy LH serum level (IU/L) 20.0 15.0 10.0 5.0 0.0 LH levels during spontaneous and stimulated
More informationFemale Reproductive Physiology. Dr Raelia Lew CREI, FRANZCOG, PhD, MMed, MBBS Fertility Specialist, Melbourne IVF
Female Reproductive Physiology Dr Raelia Lew CREI, FRANZCOG, PhD, MMed, MBBS Fertility Specialist, Melbourne IVF REFERENCE Lew, R, Natural History of ovarian function including assessment of ovarian reserve
More informationMinimising IVF related mortality and morbidity. Scott Nelson Muirhead Professor in Obstetrics & Gynaecology
Minimising IVF related mortality and morbidity Scott Nelson Muirhead Professor in Obstetrics & Gynaecology We rarely say no - so what I will cover today VTE as an example of a modifiable IVF complication
More informationEndometrial Preparation for Frozen Embryo Transfer (FET) Zitao Liu, MD, PhD New Hope Fertility Center, NY
Endometrial Preparation for Frozen Embryo Transfer (FET) Zitao Liu, MD, PhD New Hope Fertility Center, NY Natural Cycle FET Protocol for endometrial preparation N FET, including modified N FET HRT FET:
More informationDr. Ernesto Bosch Instituto Valenciano de Infertilidad Valencia, Spain. Declared no potential conflict of interest
Dr. Ernesto Bosch Instituto Valenciano de Infertilidad Valencia, Spain Declared no potential conflict of interest Is there a role for LH in elderly patients? Dr. Ernesto Bosch Instituto Valenciano de Infertilidad.
More informationInfluence ovarian stimulation on oocyte and embryo quality. Prof.Dr. Bart CJM Fauser
Influence ovarian stimulation on oocyte and embryo quality Prof.Dr. Bart CJM Fauser How to balance too much vs too little? Lecture Outline Context ovarian stimulation Impact ovarian stimulation on oocyte
More informationThe effect of luteal phase progesterone supplementation on natural frozen-thawed embryo transfer cycles
Original Article Obstet Gynecol Sci 2014;57(4):291-296 http://dx.doi.org/10.5468/ogs.2014.57.4.291 pissn 2287-8572 eissn 2287-8580 The effect of luteal phase progesterone supplementation on natural frozen-thawed
More informationHonorary Fellow of the Royal College of Obs. & Gyn. First Indian to receive FIGO s Distinguished Merit Award for Services towards women s health.
Prof.Duru Shah Founder President The PCOS Society (India) President Elect of the Indian Society for Assisted Reproduction (ISAR) Honorary Fellow of the Royal College of Obs. & Gyn. First Indian to receive
More informationJournal of Gynecology & Reproductive Medicine
Research Article Journal of Gynecology & Reproductive Medicine Ovarian Hyperstimulation Syndrome Ratio And In Vitro Fertilization Success With Gonadotrphine Releasing Hormone Trigger And 1500 IU Human
More informationSerum progesterone levels on the day of hcg trigger and ICSI outcome: a retrospective observational cohort study
International Journal of Reproduction, Contraception, Obstetrics and Gynecology Amin KV et al. Int J Reprod Contracept Obstet Gynecol. 2018 Aug;7(8):3194-3198 www.ijrcog.org DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20183316
More informationENDOCRINE CHARACTERISTICS OF ART CYCLES
ENDOCRINE CHARACTERISTICS OF ART CYCLES DOÇ. DR. SEBİHA ÖZDEMİR ÖZKAN KOCAELI UNIVERSITY, SCHOOL OF MEDICINE, DEPARTMENT OF OBSTETRICS AND GYNECOLOGY, IVF UNIT 30.04.2014, ANTALYA INTRODUCTION The endocrine
More informationTreatment of Poor Responders
Treatment of Poor Responders Pathophysiology of Poor Responders Deficiency in systemic IGF 1 levels (Bahceci, 2007) Lower intra ovarian T levels Reduced FSH receptor expression (Cai, 2007) Bahceci, 2007,
More informationVanessa N. Weitzman, M.D., Lawrence Engmann, M.D., Andrea DiLuigi, M.D., Donald Maier, M.D., John Nulsen, M.D., and Claudio Benadiva, M.D.
Comparison of luteal estradiol patch and gonadotropin-releasing hormone antagonist suppression protocol before gonadotropin stimulation versus microdose gonadotropin-releasing hormone agonist protocol
More informationIs it the seed or the soil? Arthur Leader, MD, FRCSC
The Physiological Limits of Ovarian Stimulation Is it the seed or the soil? Arthur Leader, MD, FRCSC Objectives 1. To consider how ovarian stimulation protocols work in IVF 2. To review the key events
More informationI. ART PROCEDURES. A. In Vitro Fertilization (IVF)
DFW Fertility Associates ASSISTED REPRODUCTIVE TECHNOLOGY (ART) Welcome to DFW Fertility Associates/ Presbyterian-Harris Methodist Hospital ARTS program. This document provides an overview of treatment
More informationThe effect of adding oral oestradiol to progesterone as luteal phase support in ART cycles a randomized controlled study
Clinical research The effect of adding oral oestradiol to progesterone as luteal phase support in ART cycles a randomized controlled study Ashraf Moini 1,2, Shahrzad Zadeh Modarress 3, Elham Amirchaghmaghi
More informationDisclosure. Robert Fischer Fertility Centre Hamburg Hamburg, Germany. Declared no potential conflict of interest.
Disclosure Robert Fischer Fertility Centre Hamburg Hamburg, Germany Declared no potential conflict of interest. Updates on Luteal Phase supplementation Kiev 21.09.2018 Robert Fischer MVZ Fertility Center
More informationTriggering with HCG or GnRH agonist in GnRH antagonist treated oocyte donation cycles: a randomised clinical trial
Gynecological Endocrinology, January 2009; 25(1): 60 66 HCG Triggering with HCG or GnRH agonist in GnRH antagonist treated oocyte donation cycles: a randomised clinical trial ANNA GALINDO, DANIEL BODRI,
More informationKey words: HCG versus GnRH agonist/ivf-gnrh antagonist cycles/ongoing pregnancy rates/oocyte maturation/rct
Human Reproduction Vol.20, No.10 pp. 2887 2892, 2005 Advance Access publication June 24, 2005. doi:10.1093/humrep/dei150 A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering
More informationDipartimento di Neuroscienze, Scienze Riproduttive ed Odontostomatologiche. Tecniche di sincronizzazione ovocitaria. La sincronizzazione follicolare
Dipartimento di Neuroscienze, Scienze Riproduttive ed Odontostomatologiche Tecniche di sincronizzazione ovocitaria. La sincronizzazione follicolare Carlo Alviggi The rational of Follicular synchronization
More informationPresident : Indian Society for Assisted Reproduction (ISAR) Past President FOGSI. Past Chairman ICOG. Founder Trustee Women s Empowerment Foundation
Founder President: The PCOS Society, India Honorary Fellow of the Royal College of Obst.& Gyn. Prof.Duru Shah President : Indian Society for Assisted Reproduction (ISAR) Past President FOGSI. Past Chairman
More informationFactors influencing serum progesterone level on triggering day in stimulated in vitro fertilization cycles
ORIGINAL ARTICLE pissn 2233-8233 eissn 2233-8241 Clin Exp Reprod Med 2015;42(2):67-71 Factors influencing serum progesterone level on triggering day in stimulated in vitro fertilization cycles Ju Hee Park
More informationA Tale of Three Hormones: hcg, Progesterone and AMH
A Tale of Three Hormones: hcg, Progesterone and AMH Download the Ferring AR ipad/iphone app from the Apple Store: http://bit.ly/1okk74m Human Ovarian Steroidogenesis and Gonadotrophin Stimulation Johan
More informationPremature progesterone elevation impairs implantation and live birth rates in GnRH-agonist IVF/ICSI cycles
Arch Gynecol Obstet (2010) 281:747 752 DOI 10.1007/s00404-009-1248-0 REPRODUCTIVE MEDICINE Premature progesterone elevation impairs implantation and live birth rates in GnRH-agonist IVF/ICSI cycles Esra
More informationCorifollitropin alfa or rfsh treatment flexibility options for controlled ovarian stimulation: a post hoc analysis of the Engage trial
Leader et al. Reproductive Biology and Endocrinology 2013, 11:52 RESEARCH Open Access Corifollitropin alfa or rfsh treatment flexibility options for controlled ovarian stimulation: a post hoc analysis
More informationComparison of serum and follicular fluid hormone levels with recombinant and urinary human chorionic gonadotropin during in vitro fertilization
Comparison of serum and follicular fluid hormone levels with recombinant and urinary human chorionic gonadotropin during in vitro fertilization Peter Kovacs, M.D., a Timea Kovats, M.D., a Artur Bernard,
More information(1.,, ) (2.,,, )
33 11 Vol.33 No.11 2013 11 Nov. 2013 Reproduction & Contraception doi: 10.7669/j.issn.0253-357X.2013.11.0749 E-mail: randc_journal@163.com IVF-ET 1 2 1 1 1 1 1 (1. 510150) (2. 510150) : (COH) (premature
More informationLiyan Duan 1, Shihua Bao 1, Kunming Li 1, Xiaoming Teng 1, Ling Hong 1 and Xiaoyu Zhao 2. Abstract. Introduction
doi:10.1111/jog.13305 J. Obstet. Gynaecol. Res. Vol. 43, No. 6: 1037 1042, June 2017 Comparing the long-acting and short-acting forms of gonadotropin-releasing hormone agonists in the long protocol of
More informationPrognosticating ovarian reserve by the new ovarian response prediction index
International Journal of Reproduction, Contraception, Obstetrics and Gynecology Tak A et al. Int J Reprod Contracept Obstet Gynecol. 2018 Mar;7(3):1196-1200 www.ijrcog.org DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20180917
More informationThrombosis during assisted reproduction. Scott Nelson Muirhead Chair in Obstetrics & Gynaecology
Thrombosis during assisted reproduction Scott Nelson Muirhead Chair in Obstetrics & Gynaecology ART can be as safe as natural pregnancy!! What used to be the risk of thrombosis in ART!! We can use AMH
More informationScientific Highlights: First world conference on luteinizing hormone in ART: Landing in Asia Pacific
This EXCEMED conference followed on from the First world conference on luteinizing hormone (LH) in ART, which took place in Naples in May 2016. Bringing the topic of LH to Asia Pacific provided an opportunity
More informationVaginal micronized progesterone versus intramuscular progesterone for luteal support in women undergoing in vitro fertilization embryo transfer
Vaginal micronized progesterone versus intramuscular progesterone for luteal support in women undergoing in vitro fertilization embryo transfer Mohamed F. Mitwally, M.D., H.C.L.D., a Michael P. Diamond,
More informationAgonist versus antagonist in ICSI cycles: a randomized trial and cost effectiveness analysis Badrawi A, Zaki S, Al-Inany H, Ramzy A M, Hussein M
Agonist versus antagonist in ICSI cycles: a randomized trial and cost effectiveness analysis Badrawi A, Zaki S, Al-Inany H, Ramzy A M, Hussein M Record Status This is a critical abstract of an economic
More informationIntérêt de l hcg et induction de l ovulation. Christophe Blockeel, MD, PhD Centre for Reproductive Medicine, Brussels, Belgium
Intérêt de l hcg et induction de l ovulation Christophe Blockeel, MD, PhD Centre for Reproductive Medicine, Brussels, Belgium Conflict of interest The opinions expressed in this document are the opinions
More informationInt J Clin Exp Med 2015;8(10): /ISSN: /IJCEM Pin-Xiu Huang, Ji-Hong Wei, Li-Hong Wei
Int J Clin Exp Med 2015;8(10):19072-19078 www.ijcem.com /ISSN:1940-5901/IJCEM0014127 Original Article Gonadotropin-releasing hormone agonist for oocyte triggering in endometrial preparation of letrozole
More informationCASE 41. What is the pathophysiologic cause of her amenorrhea? Which cells in the ovary secrete estrogen?
CASE 41 A 19-year-old woman presents to her gynecologist with complaints of not having had a period for 6 months. She reports having normal periods since menarche at age 12. She denies sexual activity,
More informationDoes triggering ovulation by 5000 IU of uhcg affect ICSI outcome? *
Middle East Fertility Society Journal Vol. 11, No. 2, 2006 Copyright Middle East Fertility Society Does triggering ovulation by 5000 IU of uhcg affect ICSI outcome? * Amany A.M. Shaltout, M.D. Mohamed
More informationHum. Reprod. Advance Access published March 9, 2010
Human Reproduction, Vol.00, No.0 pp. 1 6, 2010 doi:10.1093/humrep/deq059 Hum. Reprod. Advance Access published March 9, 2010 ORIGINAL ARTICLE Infertility Avoidance of weekend oocyte retrievals during GnRH
More informationUse of clomiphene to prevent premature luteinizing hormone surge during controlled ovarian hyper stimulation
International Journal of Reproduction, Contraception, Obstetrics and Gynecology Bhandari S et al. Int J Reprod Contracept Obstet Gynecol. 2016 Jun;5(6):1944-1948 www.ijrcog.org pissn 2320-1770 eissn 2320-1789
More informationThe emergence of Personalized Medicine protocols for IVF.
Individualising IVF: Introduction to the POSEIDON Concept Introduction The emergence of Personalized Medicine protocols for IVF. Differences between patients: age, ovarian reserve, BMI or presence of ovarian
More informationAre all-freeze cycles & frozen-thawed embryo transfers improving IVF outcomes?
Are all-freeze cycles & frozen-thawed embryo transfers improving IVF outcomes? Andrea Weghofer Foundation for Reproductive Medicine 2017 New York, November 16-19 Conflict of interest No relevant financial
More informationlbt lab tests t Conrolled Ovarian Hyperstimulation Dr Soheila Ansaripour
lbt lab tests t and Conrolled Ovarian Hyperstimulation Dr Soheila Ansaripour Research Instituteof Avicenna 4/23/2012 Why good prediction of poor response good prediction i of OHSS application appropriate
More informationRecent Developments in Infertility Treatment
Recent Developments in Infertility Treatment John T. Queenan Jr., MD Professor, Dept. Of Ob/Gyn University of Rochester Medical Center Rochester, NY Disclosures I don t have financial interest or other
More informationEndometrial advancement after triggering with recombinant or urinary HCG: a randomized controlled pilot study
Reproductive BioMedicine Online (2010) 21, 50 55 www.sciencedirect.com www.rbmonline.com ARTICLE Endometrial advancement after triggering with recombinant or urinary HCG: a randomized controlled pilot
More informationIn Vitro Fertilization in Clomiphene-Resistant Women with Polycystic Ovary Syndrome
Original Article Effect of Laparoscopic Ovarian Drilling on Outcomes of In Vitro Fertilization in Clomiphene-Resistant Women with Polycystic Ovary Syndrome Maryam Eftekhar, M.D. 1, Razieh Deghani Firoozabadi,
More informationSupraphysiological estradiol levels do not affect oocyte and embryo quality in oocyte donation cycles
Human Reproduction Vol.17, No.1 pp. 83 87, 2002 Supraphysiological estradiol levels do not affect oocyte and embryo quality in oocyte donation cycles Joseph E.Peña, Peter L.Chang 1, Lai-King Chan, Khaled
More informationRelevance of LH activity supplementation
Relevance of LH activity supplementation in ovulation induction Franco Lisi Servizio di Fisiopatologia della Riproduzione Clinica Villa Europa Roma, Italia Comprehension of the role of LH in follicular
More informationA prospective randomised study comparing a GnRH-antagonist versus a GnRH-agonist short protocol for ovarian stimulation in patients referred for IVF
FVV IN OBGYN, 2012, 4 (2): 82-87 Original paper A prospective randomised study comparing a GnRH-antagonist versus a GnRH-agonist short protocol for ovarian stimulation in patients referred for IVF S. GORDTS,
More informationElonva (corifollitropin alfa): A simplified, patientfocused
Product Monograph (corifollitropin alfa): A simplified, patientfocused approach to controlled ovarian stimulation TABLE OF CONTENTS (corifollitropin alfa): A simplified, patientfocused approach to controlled
More informationDoes ovulation triggering influence the risk for ovarian hyperstimulation syndrome?
Gerris Ch 20 06/12/2005 11:51 am Page 1 CHAPTER 20 Does ovulation triggering influence the risk for ovarian hyperstimulation syndrome? Shahar Kol INTRODUCTION Ovarian hyperstimulation syndrome (OHSS) is
More informationIn vitro fertilization outcome in frozen versus fresh embryo transfer in women with elevated progesterone level on the day of HCG injection: An RCT
Int J Reprod BioMed Vol. 15. No. 12. pp: 757-762, December 2017 Original article In vitro fertilization outcome in frozen versus fresh embryo transfer in women with elevated progesterone level on the day
More information2013 Sep.; 24(3):
Journal of Reproduction & Contraception doi: 10.7669/j.issn.1001-7844.2013.03.0159 2013 Sep.; 24(3):159-172 E-mail: randc_journal@163.com Comparison of the Effects and Safety of Mild Ovarian Stimulation
More informationReview Article Pharmaceutical Options for Triggering of Final Oocyte Maturation in ART
BioMed Research International, Article ID 580171, 7 pages http://dx.doi.org/10.1155/2014/580171 Review Article Pharmaceutical Options for Triggering of Final Oocyte Maturation in ART Juan Carlos Castillo,
More informationHana Park, Chung-Hoon Kim, Eun-Young Kim, Jei-Won Moon, Sung-Hoon Kim, Hee-Dong Chae, Byung-Moon Kang
Original Article Obstet Gynecol Sci 2015;58(6):481-486 http://dx.doi.org/10.5468/ogs.2015.58.6.481 pissn 2287-8572 eissn 2287-8580 Effect of second-line surgery on in vitro fertilization outcome in infertile
More information(BMI)=18.0~24.9 kg/m 2 ;
33 10 Vol.33 No.10 2013 10 Oct. 2013 Reproduction & Contraception doi: 10.7669/j.issn.0253-357X.2013.10.0672 E-mail: randc_journal@163.com - ( 400013) : () GnRH-a - () : IVF- ET 233 A (I~II 102 ) B (III~IV
More informationProgesterone vaginal capsule versus vaginal gel for luteal support in normoresponder women undergoing long agonist IVF/ICSI cycles
ORIGINAL PAPER / OBSTETRICS Ginekologia Polska 2016, vol. 87, no. 5, 372 377 Copyright 2016 Via Medica ISSN 0017 0011 DOI: 10.5603/GP.2016.0007 Progesterone vaginal capsule versus vaginal gel for luteal
More informationOriginal Article Effects of a low hcg dose of 2000 IU on clinical outcomes of high-responder women undergoing IVF/ICSI
Int J Clin Exp Med 2016;9(7):14677-14683 www.ijcem.com /ISSN:1940-5901/IJCEM0026636 Original Article Effects of a low hcg dose of 2000 IU on clinical outcomes of high-responder women undergoing IVF/ICSI
More informationEndocrinology of the Female Reproductive Axis
Endocrinology of the Female Reproductive Axis girlontheriver.com Geralyn Lambert-Messerlian, PhD, FACB Professor Women and Infants Hospital Alpert Medical School at Brown University Women & Infants BROWN
More informationInternational Journal of Women s Health and Reproduction Sciences Vol. 6, No. 2, April 2018, ISSN
http://www.ijwhr.net Open Access doi 10.15296/ijwhr.2018.31 Original Article International Journal of Women s Health and Reproduction Sciences Vol. 6, No. 2, April 2018, 187 191 ISSN 2330-4456 Comparison
More informationNuoveprospettive per la faseluteale.
Nuoveprospettive per la faseluteale. Dr. Ilario Candeloro Centro di Procreazione Medicalmente Assistita ASST Papa Giovanni XXIII Bergamo The role of LH and progesterone in the luteal phase Totally responsible
More informationFemale Reproductive System. Lesson 10
Female Reproductive System Lesson 10 Learning Goals 1. What are the five hormones involved in the female reproductive system? 2. Understand the four phases of the menstrual cycle. Human Reproductive System
More informationOVULATION INDUCTION. Ori Nevo, M.D., a Talia Eldar-Geva, M.D., Ph.D., b Shahar Kol, M.D., a and Joseph Itskovitz-Eldor, M.D., D.Sc.
FERTILITY AND STERILITY VOL. 79, NO. 5, MAY 2003 Copyright 2003 American Society for Reproductive Medicine Published by Elsevier Inc. Printed on acid-free paper in U.S.A. OVULATION INDUCTION Lower levels
More informationDual trigger of triptorelin and HCG optimizes clinical outcome for high ovarian responder in GnRH-antagonist protocols
/, 2018, Vol. 9, (No. 4), pp: 5337-5343 Dual trigger of triptorelin and HCG optimizes clinical outcome for high ovarian responder in GnRH-antagonist protocols Saijiao Li 1,*, Danni Zhou 1,*, Tailang Yin
More informationSynchronization between embryo development and endometrium is a contributing factor for rescue ICSI outcome
Reproductive BioMedicine Online (2012) 24, 527 531 www.sciencedirect.com www.rbmonline.com ARTICLE Synchronization between embryo development and endometrium is a contributing factor for rescue ICSI outcome
More informationChen et al. Reproductive Biology and Endocrinology (2018) 16:36 https://doi.org/ /s z
Chen et al. Reproductive Biology and Endocrinology (2018) 16:36 https://doi.org/10.1186/s12958-018-0352-z RESEARCH Open Access Pregnancy outcomes of PCOS overweight/ obese patients after controlled ovarian
More information